ArticleCureus2025
Impact of Continuous Positive Airway Pressure Therapy on Gastroesophageal Reflux Disease in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to evaluate the effects of continuous positive airway pressure (CPAP) therapy on gastroesophageal reflux disease (GERD) symptom severity and obstructive sleep apnea (OSA) severity in patients diagnosed with both conditions over a one-month period, using validated tools to examine CPAP adherence and adverse events. MATERIALS AND
methodsThis prospective, single-center cohort study was conducted at the Department of Respiratory Medicine between May 2024 and March 2025. Eighty-nine adults aged 18-75 years with moderate-to-severe OSA (apnea-hypopnea index as AHI ≥ 15 events/h) confirmed by polysomnography and GERD diagnosed via clinical symptoms or endoscopic evidence were enrolled. The exclusion criteria included prior CPAP use, severe comorbidities, and inability to tolerate CPAP use. Baseline assessments included the Gastroesophageal Reflux Disease Questionnaire (GERD-Q) for GERD symptoms, Epworth Sleepiness Scale (ESS) for daytime sleepiness, and polysomnography for AHI, peripheral oxygen saturation (SpO
resultsThe study included 89 patients, with 55 male patients (61.8%) and 34 (38.2%) female patients. Of the 89 patients (mean age 55.04 ± 6.48 years, mean body mass index 31.84 ± 2.5 kg/m²), 72 (80.9%) achieved adequate CPAP adherence. Adequate adherence significantly reduced the GERD-Q scores (p < 0.05), AHI (p < 0.05), ODI (p < 0.05), and ESS scores (p < 0.05), with no significant change in SpO
conclusionAdequate CPAP adherence significantly improved GERD and OSA severity without adverse effects, supporting its use as the primary therapy for patients with both conditions. Targeted interventions addressing smoking and sleep positions may further enhance these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.